MCID: THR001
MIFTS: 42

Thrombocytopenia Due to Platelet Alloimmunization

Categories: Rare diseases, Blood diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 14 69
Autoimmune Thrombocytopenia 25 29 52 69
Immune Thrombocytopenia 12 50 25
Immune Thrombocytopenic Purpura 25 69
Thrombocytopenia Due to Immune Destruction 12
Autoimmune Thrombocytopenic Purpura 25
Idiopathic Thrombocytopenic Purpura 25
Auto-Immune Thrombocytopenia 12
Werlhof Disease 25
Itp 25

Classifications:



External Ids:

Disease Ontology 12 DOID:1587
NCIt 47 C3991
SNOMED-CT 64 2897005
UMLS 69 C0272286

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

Genetics Home Reference : 25 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cell fragments called platelets that are needed for normal blood clotting.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as autoimmune thrombocytopenia, is related to thrombocytopenic purpura, autoimmune and autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is ITGA2B (Integrin Subunit Alpha 2b), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Regulation of actin cytoskeleton. The drugs rituximab and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and bone, and related phenotypes are hematopoietic system and cellular

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 3 Thrombocytopenia 4
Thrombocytopenia 2 Thrombocytopenia 5
Thrombocytopenia 6 Acquired Thrombocytopenia
Thrombocytopenia Due to Platelet Alloimmunization Primary Thrombocytopenia
Myh9 Related Thrombocytopenia Mastl-Related Thrombocytopenia 2
Gata1-Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Related Disease Score Top Affiliating Genes
1 thrombocytopenic purpura, autoimmune 30.9 ITGA2B MPL SELP THPO
2 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 11.9
3 evans' syndrome 11.0
4 autoimmune lymphoproliferative syndrome, type v 10.8
5 antiphospholipid syndrome, familial 10.8
6 inflammatory bowel disease 18 10.5 MPL THPO
7 hypotrichosis, congenital, with juvenile macular dystrophy 10.5 MPL THPO
8 alopecia-mental retardation syndrome 1 10.5 MPL THPO
9 thrombocytopenia, congenital amegakaryocytic 10.4 MPL THPO
10 fetal hydantoin syndrome 10.4 ITGA2 ITGA2B
11 optic nerve neoplasm 10.4 ITGA2B SELP
12 prostatic cyst 10.3 ITGA2B THPO
13 parasitic helminthiasis infectious disease 10.3 ITGA2B SELP
14 essential thrombocythemia 10.3 GP9 ITGA2B
15 chronic inflammatory demyelinating polyneuritis 10.2 CD40LG THPO
16 microcystic adenoma 10.1 ITGA2B THPO
17 hereditary amyloidosis 10.1 CD40LG SELP
18 hypertrophic elongation of cervix 10.1 CD40LG ITGA2B
19 thrombocytopenia-absent radius syndrome 10.1 MPL THPO
20 tuberculoid leprosy 10.0 CD40LG SELP
21 third branchial cleft anomaly 10.0 ITGA2B MYH9
22 granulomatous hepatitis 10.0 MPL SELP THPO
23 hypocalciuric hypercalcemia, type i 10.0 ITGA2B MPL THPO
24 dentin dysplasia 10.0 CD40LG THPO
25 blood coagulation disease 10.0 MPL THPO
26 iida kannari syndrome 9.9 CD40LG THPO
27 spinal polio 9.9 CD40LG ITGA2B THPO
28 lacrimal system cancer 9.9 CD40LG ITGA2B THPO
29 parenchymatous neurosyphilis 9.8 CD40LG MYH9
30 thrombocytopenia 9.8
31 fallopian tube cystadenofibroma 9.8 CD40LG MYH9
32 vascular skin disease 9.8 CD40LG MYH9
33 alopecia areata 9.8 CD40LG MYH9
34 malignant eyelid melanoma 9.7 CD40LG MYH9
35 basilar artery insufficiency 9.7 ITGA2B MPL SELP THPO
36 blood group incompatibility 9.7 CD40LG MYH9
37 osteogenesis imperfecta, type vii 9.7 CD40LG GP9 SELP
38 ganglioneuroblastoma 9.6 CD40LG MYH9
39 transmitted_by 9.6 CD40LG MYH9
40 perichondritis of auricle 9.5 CD40LG ITGA2B MPL THPO
41 partial sensory epilepsy 9.5 CD40LG ITGA2B MPL THPO
42 mixed germ cell-sex cord neoplasm 9.5 CD40LG SELP
43 thrombomodulin anomalies, familial 9.4 GP9 ITGA2 ITGA2B SELP
44 bleeding disorder, platelet-type, 16, autosomal dominant 9.4 GP9 ITGA2 ITGA2B SELP
45 myocardial infarction 9.2 CD40LG ITGA2 ITGA2B SELP
46 autonomic peripheral neuropathy 9.0 CD40LG ITGA2 ITGA2B MPL THPO
47 ocular hyperemia 9.0 CD40LG GP9 ITGA2B MPL THPO
48 immunodeficiency 21 8.7 GP9 ITGA2 ITGA2B MYH9 THPO
49 tracheal cancer 8.3 GP9 ITGA2 ITGA2B MPL MYH9 THPO
50 myeloproliferative neoplasm 7.7 CD40LG GP9 ITGA2B MPL MYH9 SELP

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CD40LG GP9 ITGA2 ITGA2B MPL MYH9
2 cellular MP:0005384 9.73 CD40LG ITGA2 ITGA2B MPL MYH9 SELP
3 homeostasis/metabolism MP:0005376 9.5 SELP THPO CD40LG ITGA2 ITGA2B MPL
4 immune system MP:0005387 9.1 CD40LG ITGA2B MPL MYH9 SELP THPO

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2 174722-31-7 10201696
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
3
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
4
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
5
Hydroxychloroquine Approved Phase 4 118-42-3 3652
6
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
7
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
8
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
9
Caffeic acid Experimental Phase 4,Phase 3 331-39-5 1549111
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antiemetics Phase 4,Phase 3,Phase 2
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
14 Autonomic Agents Phase 4,Phase 3,Phase 2
15 BB 1101 Phase 4,Phase 2,Phase 3
16 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
18 glucocorticoids Phase 4,Phase 3,Phase 2
19 Hormone Antagonists Phase 4,Phase 3,Phase 2
20 Hormones Phase 4,Phase 3,Phase 2
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
23 Antioxidants Phase 4,Phase 2,Phase 3
24 Protective Agents Phase 4,Phase 2,Phase 3
25 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
26
protease inhibitors Phase 4,Phase 3,Phase 2
27 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Antimalarials Phase 4,Phase 3
29 Antimetabolites Phase 4,Phase 3,Phase 2
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
31 Antiparasitic Agents Phase 4,Phase 3
32 Antiprotozoal Agents Phase 4,Phase 3
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
35
Proton pump inhibitors Phase 4,Phase 3
36 Tin Fluorides Phase 4
37 Antimitotic Agents Phase 4
38 Antineoplastic Agents, Phytogenic Phase 4
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
42
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
43
Selenium Approved, Vet_approved Phase 2, Phase 3 7782-49-2
44
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
45
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
46
Adenosine Approved, Investigational Phase 3 58-61-7 60961
47
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
48
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 3 24280-93-1 446541
50
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 125)

id Name Status NCT ID Phase Drugs
1 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
2 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
3 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
4 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
5 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
6 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Recruiting NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
7 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
8 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
9 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Not yet recruiting NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
10 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
11 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
12 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
13 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
14 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care
15 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
16 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
17 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients Completed NCT01444417 Phase 3 Romiplostim;Placebo
18 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia Completed NCT01349790 Phase 3 NewGam
19 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
20 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) Completed NCT01506414 Phase 3 rhTPO in combination with Rituximab
21 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
22 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
23 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed NCT01520909 Phase 3 Eltrombopag;Placebo
24 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3 recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
25 Rituximab as Second Line Treatment for ITP Completed NCT00344149 Phase 3 Rituximab (Mabthera)
26 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Completed NCT01525836 Phase 3 rituximab; recombinant human thrombopoietin (rhTPO);Rituximab
27 A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. Completed NCT00376077 Phase 3 Methylprednisolone and IVIG;Placebo and IVIG
28 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Recruiting NCT02270801 Phase 3 rhTPO
29 A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Recruiting NCT03164915 Phase 3
30 This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) Recruiting NCT02859909 Phase 3
31 Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Recruiting NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
32 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy Recruiting NCT02391272 Phase 3 rhTPO
33 The PROLONG Trial - Rituximab Maintenance Therapy in ITP Recruiting NCT03010202 Phase 3 Dexamethasone;Rituximab
34 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Recruiting NCT01621204 Phase 3 Eltrombopag;IVIG infusion
35 DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients Recruiting NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
36 H. Pylori Eradication for Moderate ITP Recruiting NCT03177629 Phase 3 treatment : H. pylori eradication
37 Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients Recruiting NCT02877212 Phase 3 Eltrombopag
38 Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP. Active, not recruiting NCT02279173 Phase 3 Romiplostim
39 Thrombocytopenia in Gestational Period Active, not recruiting NCT02751593 Phase 2, Phase 3 Dexamethasone
40 Eltrombopag Phase III Study In Chinese Chronic ITP Patients Active, not recruiting NCT01762761 Phase 3 eltrombopag;placebo
41 Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate Not yet recruiting NCT03156452 Phase 3 Mycophenolate Mofetil;Prednisolone
42 Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia Not yet recruiting NCT02649504 Phase 3 Rituximab;Dexamethasone;Mycophenolate mofetil;Placebo
43 Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP Not yet recruiting NCT03252457 Phase 3 Decitabine;Dexamethasone
44 The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP) Terminated NCT01226524 Phase 2, Phase 3 Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
45 A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic T Terminated NCT01433978 Phase 3 Eltrombopag;Avatrombopag
46 A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP) Withdrawn NCT02203422 Phase 3 Cyclosporin A;rhTPO
47 A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP) Withdrawn NCT02137681 Phase 3 Rituximab
48 All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT01882127 Phase 3 All-Trans Retinoid Acid(ATRA);Dexamethasone
49 Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT01734057 Phase 3 recombinant human thrombopoietin (rhTPO); rituximab;Dexamethasone
50 Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Unknown status NCT01610180 Phase 2 Eltrombopag Olamine

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

id Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

39
Testes, Liver, Bone, T Cells, B Cells, Bone Marrow, Spleen

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Variations for Thrombocytopenia Due to Platelet Alloimmunization

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 GP9 ITGA2 ITGA2B MPL SELP THPO
2 12.27 ITGA2 ITGA2B MYH9
3
Show member pathways
11.79 GP9 ITGA2 ITGA2B
4 11.63 GP9 ITGA2 ITGA2B
5 11.52 ITGA2 ITGA2B MPL THPO
6 11.38 ITGA2 ITGA2B THPO
7 11.35 CD40LG SELP
8 11.28 ITGA2 ITGA2B
9
Show member pathways
11.25 GP9 ITGA2B MPL THPO
10 11.21 GP9 ITGA2 ITGA2B
11 11.18 CD40LG SELP
12 11.16 GP9 ITGA2B
13 11.04 ITGA2 ITGA2B
14 10.91 GP9 ITGA2 ITGA2B THPO
15 10.52 GP9 ITGA2

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.91 CD40LG GP9 ITGA2 ITGA2B MPL MYH9
2 integral component of plasma membrane GO:0005887 9.72 CD40LG GP9 ITGA2B MPL SELP
3 focal adhesion GO:0005925 9.58 ITGA2 ITGA2B MYH9
4 cell surface GO:0009986 9.56 CD40LG ITGA2 ITGA2B MPL
5 external side of plasma membrane GO:0009897 9.26 CD40LG ITGA2 ITGA2B SELP
6 platelet alpha granule membrane GO:0031092 9.16 ITGA2B SELP
7 integrin complex GO:0008305 8.8 ITGA2 ITGA2B MYH9

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.58 ITGA2 MPL THPO
2 cell adhesion GO:0007155 9.55 GP9 ITGA2 ITGA2B MYH9 SELP
3 integrin-mediated signaling pathway GO:0007229 9.43 ITGA2 ITGA2B MYH9
4 platelet aggregation GO:0070527 9.37 ITGA2B MYH9
5 leukocyte cell-cell adhesion GO:0007159 9.32 CD40LG SELP
6 thrombopoietin-mediated signaling pathway GO:0038163 8.96 MPL THPO
7 positive regulation of leukocyte migration GO:0002687 8.8 ITGA2 ITGA2B SELP

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....